Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

U3-1402, a novel HER3-targeting antibody-drug conjugate, for the treatment of Colorectal Cancer.

Koganemaru S, Kuboki Y, Koga Y, Kojima T, Yamauchi M, Maeda N, Kagari T, Hirotani K, Yasunaga M, Matsumura Y, Doi T.

Mol Cancer Ther. 2019 Aug 8. pii: molcanther.0452.2019. doi: 10.1158/1535-7163.MCT-19-0452. [Epub ahead of print]

PMID:
31395690
2.

An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC.

Yonesaka K, Takegawa N, Watanabe S, Haratani K, Kawakami H, Sakai K, Chiba Y, Maeda N, Kagari T, Hirotani K, Nishio K, Nakagawa K.

Oncogene. 2019 Feb;38(9):1398-1409. doi: 10.1038/s41388-018-0517-4. Epub 2018 Oct 9.

PMID:
30302022
3.

Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a.

Burvenich IJG, Parakh S, Lee FT, Guo N, Liu Z, Gan HK, Rigopoulos A, O'Keefe GJ, Gong SJ, Goh YW, Tochon-Danguy H, Scott FE, Kotsuma M, Hirotani K, Senaldi G, Scott AM.

Theranostics. 2018 Jul 30;8(15):4199-4209. doi: 10.7150/thno.25575. eCollection 2018.

4.

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.

Yonesaka K, Haratani K, Takamura S, Sakai H, Kato R, Takegawa N, Takahama T, Tanaka K, Hayashi H, Takeda M, Kato S, Maenishi O, Sakai K, Chiba Y, Okabe T, Kudo K, Hasegawa Y, Kaneda H, Yamato M, Hirotani K, Miyazawa M, Nishio K, Nakagawa K.

Clin Cancer Res. 2018 Jun 1;24(11):2653-2664. doi: 10.1158/1078-0432.CCR-17-2852. Epub 2018 Mar 12.

5.

Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.

Bandyopadhyay A, Favours E, Phelps DA, Pozo VD, Ghilu S, Kurmashev D, Michalek J, Trevino A, Guttridge D, London C, Hirotani K, Zhang L, Kurmasheva RT, Houghton PJ.

Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26870. Epub 2017 Oct 28.

6.

Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer.

Yonesaka K, Hirotani K, von Pawel J, Dediu M, Chen S, Copigneaux C, Nakagawa K.

Lung Cancer. 2017 Mar;105:1-6. doi: 10.1016/j.lungcan.2016.12.018. Epub 2017 Jan 9.

PMID:
28236978
7.

Translocation of Tektin 3 to the equatorial segment of heads in bull spermatozoa exposed to dibutyryl cAMP and calyculin A.

Tsukamoto M, Hiyama E, Hirotani K, Gotoh T, Inai T, Iida H.

Mol Reprod Dev. 2017 Jan;84(1):30-43. doi: 10.1002/mrd.22763. Epub 2016 Dec 27.

PMID:
27883267
8.

Development of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity.

Nagase-Zembutsu A, Hirotani K, Yamato M, Yamaguchi J, Takata T, Yoshida M, Fukuchi K, Yazawa M, Takahashi S, Agatsuma T.

Cancer Sci. 2016 May;107(5):674-81. doi: 10.1111/cas.12915. Epub 2016 Apr 26.

9.

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.

Yonesaka K, Hirotani K, Kawakami H, Takeda M, Kaneda H, Sakai K, Okamoto I, Nishio K, Jänne PA, Nakagawa K.

Oncogene. 2016 Feb 18;35(7):878-86. doi: 10.1038/onc.2015.142. Epub 2015 May 11.

PMID:
25961915
10.

Validation of MIMGO: a method to identify differentially expressed GO terms in a microarray dataset.

Yamada Y, Sawada H, Hirotani K, Oshima M, Satou K.

BMC Res Notes. 2012 Dec 12;5:680. doi: 10.1186/1756-0500-5-680.

11.

Synthesis and antitumor activity of novel pyrimidinyl pyrazole derivatives. III. Synthesis and antitumor activity of 3-phenylpiperazinyl-1-trans-propenes.

Naito H, Ohsuki S, Atsumi R, Minami M, Mochizuki M, Hirotani K, Kumazawa E, Ejima A.

Chem Pharm Bull (Tokyo). 2005 Feb;53(2):153-63.

12.

A novel mitochondrial C1-tetrahydrofolate synthetase is upregulated in human colon adenocarcinoma.

Sugiura T, Nagano Y, Inoue T, Hirotani K.

Biochem Biophys Res Commun. 2004 Feb 27;315(1):204-11.

PMID:
15013446
13.

In vivo malignant phenotype of hst-1-transfected cells regulated by paracrine endothelial cell growth stimulation by HST-1.

Aonuma M, Murakami K, Hirotani K, Horiuchi T, Sakamoto H, Terada M, Tanaka NG.

Angiogenesis. 1998;2(2):143-52.

PMID:
14517470
14.

Tumorigenicity depends on angiogenic potential of tumor cells: dominant role of vascular endothelial growth factor and/or fibroblast growth factors produced by tumor cells.

Aonuma M, Iwahana M, Nakayama Y, Hirotani K, Hattori C, Murakami K, Shibuya M, Tanaka NG.

Angiogenesis. 1998;2(1):57-66.

PMID:
14517376
15.

Synthesis and mechanism of action of novel pyrimidinyl pyrazole derivatives possessing antiproliferative activity.

Ohki H, Hirotani K, Naito H, Ohsuki S, Minami M, Ejima A, Koiso Y, Hashimoto Y.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3191-3.

PMID:
12372531
16.

Synthesis and antitumor activity of novel pyrimidinyl pyrazole derivatives. II. Optimization of the phenylpiperazine moiety of 1-[5-methyl-1-(2-pyrimidinyl)-4-pyrazolyl]-3-phenylpiperazinyl-1-trans-propenes.

Naito H, Ohsuki S, Sugimori M, Atsumi R, Minami M, Nakamura Y, Ishii M, Hirotani K, Kumazawa E, Ejima A.

Chem Pharm Bull (Tokyo). 2002 Apr;50(4):453-62.

17.

Synthesis and antitumor activity of novel pyrimidinyl pyrazole derivatives.

Naito H, Sugimori M, Mitsui I, Nakamura Y, Iwahana M, Ishii M, Hirotani K, Kumazawa E, Ejima A.

Chem Pharm Bull (Tokyo). 1999 Dec;47(12):1679-84.

PMID:
10748712
18.

Synthesis and antitumor activity of novel benzophenone derivatives.

Kumazawa E, Hirotani K, Burford SC, Kawagoe K, Miwa T, Mitsui I, Ejima A.

Chem Pharm Bull (Tokyo). 1997 Sep;45(9):1470-4.

PMID:
9331999
19.

Angiogenic factor of a rat mammary tumor cell line (RMT-1) (I). Secretion of two distinct angiogenic factors into serum-free conditioned medium by RMT-1 cells.

Oikawa T, Hirotani K, Yamaoka K, Katayama T, Iwaguchi T, Ito H, Morita I, Murota S, Tominaga T, Hiragun A.

Cancer Lett. 1991 Jul 26;59(1):57-66.

PMID:
1715234
20.

Inhibition of angiogenesis by bleomycin and its copper complex.

Oikawa T, Hirotani K, Ogasawara H, Katayama T, Ashino-Fuse H, Shimamura M, Iwaguchi T, Nakamura O.

Chem Pharm Bull (Tokyo). 1990 Jun;38(6):1790-2.

PMID:
1698565
21.

Inhibition of angiogenesis by vitamin D3 analogues.

Oikawa T, Hirotani K, Ogasawara H, Katayama T, Nakamura O, Iwaguchi T, Hiragun A.

Eur J Pharmacol. 1990 Mar 20;178(2):247-50. Erratum in: Eur J Pharmacol 1990 Jul 17;182(3):616.

PMID:
1691714
22.

A highly potent antiangiogenic activity of retinoids.

Oikawa T, Hirotani K, Nakamura O, Shudo K, Hiragun A, Iwaguchi T.

Cancer Lett. 1989 Nov 30;48(2):157-62.

PMID:
2479461
23.

Powerful antiangiogenic activity of herbimycin A (named angiostatic antibiotic).

Oikawa T, Hirotani K, Shimamura M, Ashino-Fuse H, Iwaguchi T.

J Antibiot (Tokyo). 1989 Jul;42(7):1202-4. No abstract available.

24.

[A case study. Nursing of a patient undergoing radiotherapy for lung cancer].

Anno T, Hirotani K, Miyake H.

Kango Gijutsu. 1989 May;35(7):744-8. Japanese. No abstract available.

PMID:
2593348
25.

A new method of esophageal anastomosis by means of the devised ring.

Daido R, Kano M, Hirotani K, Oashi I, Nakamura M.

Jpn J Surg. 1971 Mar;1(1):63-71. No abstract available.

PMID:
5173066
26.

[Esophageal anastomosis with a joining tube].

Daido R, Kano M, Hirotani K, Funada M, Nakamura M.

Iryo. 1970 Jan;24(1):15-20. Japanese. No abstract available.

PMID:
5438811
27.

[Adrenocortical function in liver diseases].

Hirotani K.

Nihon Naibunpi Gakkai Zasshi. 1969 Dec 21;45(9):954-67. Japanese. No abstract available.

PMID:
4312899
28.

[Reconstruction of the esophagus by our method].

Daido R, Kano M, Hirotani K, Nakamura M, Funada M.

Iryo. 1969 Sep;23(9):1205-10. Japanese. No abstract available.

PMID:
5360008
29.

[Transplantation of the jejunum in temporary esophagoplasty for esophageal neoplasms].

Daido R, Kano M, Hirotani K, Nishio Y, Funada M.

Geka Chiryo. 1968 Apr;18(4):379-87. Japanese. No abstract available.

PMID:
5696116
30.

A method of total gastrectomy followed by a d-shaped esophageal anastomosis.

Daido R, Kano M, Hirotani K, Nishio Y, Funada M.

Surgery. 1967 Nov;62(5):865-71. No abstract available.

PMID:
4964127
31.

[Basic studies on esophageal reconstruction using the jejunum].

Daido R, Kano M, Hirotani K, Nishio Y, Funada M.

Kyobu Geka. 1967 Sep;20(9):623-32. Japanese. No abstract available.

PMID:
5626117
32.

[Lymph node staining by pigment injection via the lymphatic vessels--with special reference to radical resection of rectal and gastric cancer].

Daido R, Shikano M, Hirotani K, Nishio Y, Ochiai J.

Shujutsu. 1967 Aug;21(8):799-804. Japanese. No abstract available.

PMID:
4170762
33.

[Ileocecoplasty for pain of the ileocecum and chronic constipation].

Daido R, Kano M, Hirotani K, Nishio Y, Funada M.

Iryo. 1967 Jun;21(6):670-5. Japanese. No abstract available.

PMID:
6079027
34.

[Histological study of the transplanted intestine--with reference to changes in the nerve cells].

Daido R, Kano M, Hirotani K, Nishio Y, Funada M.

Iryo. 1967 May;21(5):592-6. Japanese. No abstract available.

PMID:
6078190
35.

[New trial for chronic constipation, with reference to jejunum transplantation in the colon].

Daido R, Kano M, Hirotani K, Nishio Y, Funada M.

Iryo. 1967 May;21(5):570-4. Japanese. No abstract available.

PMID:
6078188
36.

[Our method of ileocecal plasty for appendectomy complications].

Dido R, Sikano M, Hirotani K, Nishio Y, Funada M.

Shujutsu. 1967 May;21(5):451-6. Japanese. No abstract available.

PMID:
6074583
37.

[Lymph node resection by infragastric approach for gastric cancer].

Daido R, Kano M, Hirotani K, Nishio Y, Funada M.

Shujutsu. 1967 Apr;21(4):361-7. Japanese. No abstract available.

PMID:
6063404
38.

[Study on lymphatic metastasis of stomach cancer by infusion of dyes through a gastroscope].

Daido R, Ochiai J, Kano M, Hirotani K, Nishio Y.

Iryo. 1967 Jan;21(1):81-5. Japanese. No abstract available.

PMID:
6037010
39.

[Abdomino-perineal resection preserving the sphincter].

Daido R, Ochiai J, Kano M, Fujita Y, Hirotani K.

Iryo. 1966 Oct;20(10):1023-31. Japanese. No abstract available.

PMID:
5978325
40.

[Our proctosigmoidectomy with preservation of the anal sphincter].

Daido R, Ochiai J, Kano M, Hirotani K.

Shujutsu. 1966 Apr;20(4):273-82. Japanese. No abstract available.

PMID:
5960565
41.

[Total gastrectomy with esophagojejunostomy with special reference to "d" type anastomosis].

Daido R, Kano M, Ochiai J, Hirotani K.

Shujutsu. 1965 Dec;19(12):957-64. Japanese. No abstract available.

PMID:
5869856
42.

[Our new measures for the prevention of early complications of gastrectomy].

Daido R, Kano M, Ochiai J, Hirotani K.

Shujutsu. 1965 Oct;19(10):777-85. Japanese. No abstract available.

PMID:
5888126

Supplemental Content

Loading ...
Support Center